Corrigendum to: Introduction to the chemistry and pharmacology of psychedelic drugs
Scott R. Walker, Glenn A. Pullella, Matthew Piggott, Peter J. Duggan
Australian Journal of Chemistry January 19, 2024 correction DOI: 10.1071/ch23050_co (opens in new tab)
Study at a glance
AI-extracted from the abstract| Keywords | Pharmacology Biocatalysis Biochemistry Ionic liquid |
|---|
Abstract
© 2024 The Author(s) (or their employer(s)). Published by CSIRO Publishing. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND)
Citations in the library
Cites 84
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness Journal of Psychopharmacology September 28, 2011
- Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences September 3, 2002
- Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences December 17, 1984
and 79 more in the library